Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Healthcare Medical Devices
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Business Wire May 20, 2024

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA(TM)) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Business Wire May 16, 2024

Pulse Biosciences Enhances Executive Leadership Team

Business Wire May 14, 2024

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Business Wire May 9, 2024

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Business Wire May 7, 2024

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Business Wire May 2, 2024

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Business Wire April 24, 2024

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Business Wire March 28, 2024

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Business Wire March 28, 2024

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Business Wire March 14, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System

Business Wire March 8, 2024

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA(TM) 360° Cardiac Catheter First-in-Human Feasibility Study

Business Wire February 14, 2024

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Business Wire January 31, 2024

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA(TM) Cardiac Clamp

Business Wire January 2, 2024

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX(TM) Nanosecond Pulsed Field Ablation (nsPFA(TM)) Cardiac Catheter

Business Wire December 20, 2023

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Business Wire November 21, 2023

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Business Wire November 15, 2023

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

Business Wire November 13, 2023

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

Business Wire November 10, 2023

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

Business Wire October 30, 2023